Harbor Capital Advisors Inc. Purchases 111,185 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Harbor Capital Advisors Inc. grew its position in Option Care Health, Inc. (NASDAQ:OPCH) by 115.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 207,560 shares of the company’s stock after purchasing an additional 111,185 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.12% of Option Care Health worth $6,497,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Comerica Bank increased its stake in Option Care Health by 6.5% in the 1st quarter. Comerica Bank now owns 760,915 shares of the company’s stock valued at $25,521,000 after buying an additional 46,639 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Option Care Health by 182.9% in the first quarter. Janus Henderson Group PLC now owns 227,135 shares of the company’s stock valued at $7,617,000 after acquiring an additional 146,837 shares during the last quarter. Edgestream Partners L.P. raised its holdings in Option Care Health by 96.8% during the second quarter. Edgestream Partners L.P. now owns 351,476 shares of the company’s stock worth $9,736,000 after acquiring an additional 172,845 shares in the last quarter. XTX Topco Ltd bought a new stake in Option Care Health during the second quarter worth about $973,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Option Care Health by 1.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,760,482 shares of the company’s stock valued at $59,047,000 after purchasing an additional 23,676 shares during the last quarter. 98.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Option Care Health news, CFO Michael H. Shapiro sold 23,217 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total value of $718,566.15. Following the completion of the sale, the chief financial officer now owns 247,317 shares of the company’s stock, valued at $7,654,461.15. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Elizabeth Quadros Betten sold 47,531 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $31.09, for a total transaction of $1,477,738.79. Following the completion of the transaction, the director now directly owns 21,339 shares in the company, valued at $663,429.51. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael H. Shapiro sold 23,217 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total transaction of $718,566.15. Following the sale, the chief financial officer now directly owns 247,317 shares of the company’s stock, valued at $7,654,461.15. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.64% of the stock is owned by insiders.

Option Care Health Price Performance

Shares of OPCH opened at $24.11 on Friday. The company’s 50-day moving average is $30.49 and its 200-day moving average is $29.91. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.36. The firm has a market capitalization of $4.10 billion, a PE ratio of 20.26, a PEG ratio of 1.74 and a beta of 1.32. Option Care Health, Inc. has a fifty-two week low of $22.84 and a fifty-two week high of $34.63.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. Option Care Health had a return on equity of 15.30% and a net margin of 4.37%. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.22 billion. Equities analysts forecast that Option Care Health, Inc. will post 1.23 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OPCH. Jefferies Financial Group cut Option Care Health from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $38.00 to $26.00 in a research note on Thursday. JMP Securities upped their price target on shares of Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a research report on Monday, September 30th. Barrington Research decreased their price objective on shares of Option Care Health from $40.00 to $32.00 and set an “outperform” rating for the company in a research report on Thursday. Truist Financial dropped their target price on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a report on Friday. Finally, Bank of America cut Option Care Health from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $43.00 to $29.00 in a report on Wednesday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.60.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.